Please Wait
Applying Filters...
menu
    • menu
    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    An Enquiry

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    Arlanda is your partner for the Brazil market.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    CT1812

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cognition Advances Zervimesine for Lewy Body Dementia Psychosis
    Cognition Advances Zervimesine for Lewy Body Dementia Psychosis

    02 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/02/3247262/0/en/Cognition-Therapeutics-Advancing-Zervimesine-CT1812-for-Dementia-with-Lewy-Bodies-DLB-Psychosis.html

    GLOBENEWSWIRE
    02 Mar 2026
    Share Share
    Cognition Therapeutics Extends Zervimesine Access Program
    Cognition Therapeutics Extends Zervimesine Access Program

    05 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/05/3232883/0/en/Cognition-Therapeutics-Extends-Expanded-Access-Program-for-Zervimesine-CT1812-in-Dementia-with-Lewy-Bodies.html

    GLOBENEWSWIRE
    05 Feb 2026
    Share Share
    Cognition Therapeutics Wraps FDA Type C Meeting For Zervimesine
    Cognition Therapeutics Wraps FDA Type C Meeting For Zervimesine

    27 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/27/3226367/0/en/Cognition-Therapeutics-Completes-Type-C-Meeting-with-FDA-for-Zervimesine-CT1812-in-Dementia-with-Lewy-Bodies.html

    GLOBENEWSWIRE
    27 Jan 2026
    Share Share
    Cognition Phase 2 Results Show Zervimesine Slows Dementia DLB
    Cognition Phase 2 Results Show Zervimesine Slows Dementia DLB

    06 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/06/3213500/0/en/Cognition-Therapeutics-Publishes-Phase-2-Clinical-Results-Showing-Zervimesine-s-Potential-to-Slow-the-Progression-of-Dementia-with-Lewy-Bodies.html

    GLOBENEWSWIRE
    06 Jan 2026
    Share Share
    Cognition Therapeutics Completes CT1812 Enrollment in DLB Trial
    Cognition Therapeutics Completes CT1812 Enrollment in DLB Trial

    03 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/03/3198763/0/en/Cognition-Therapeutics-Reaches-Full-Enrollment-in-Expanded-Access-Program-for-Zervimesine-CT1812-in-Dementia-with-Lewy-Bodies.html

    GLOBENEWSWIRE
    03 Dec 2025
    Share Share
    Cognition Therapeutics Unveils Zervimesine Phase 3 Plan in AD
    Cognition Therapeutics Unveils Zervimesine Phase 3 Plan in AD

    01 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/01/3196911/0/en/Cognition-Therapeutics-Presents-Phase-3-Plan-for-Zervimesine-CT1812-in-Alzheimer-s-Disease-at-Clinical-Trials-on-Alzheimer-s-Disease-CTAD-Conference.html

    GLOBENEWSWIRE
    01 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.